SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

X4 Pharmaceuticals, Inc. – ‘10-K’ for 12/31/23 – ‘XML’

On:  Thursday, 3/21/24, at 5:08pm ET   ·   For:  12/31/23   ·   Accession #:  1628280-24-12578   ·   File #:  1-38295

Previous ‘10-K’:  ‘10-K’ on 3/21/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   28 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/21/24  X4 Pharmaceuticals, Inc.          10-K       12/31/23   93:9.5M                                   Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.97M 
 2: EX-10.37    Material Contract                                   HTML     33K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     27K 
 7: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     49K 
                Awarded Compensation                                             
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     31K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     31K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     28K 
13: R1          Cover                                               HTML     95K 
14: R2          Audit Information                                   HTML     32K 
15: R3          Consolidated Balance Sheets                         HTML    124K 
16: R4          Consolidated Balance Sheets (Parenthetical)         HTML     37K 
17: R5          Consolidated Statements of Operations and           HTML    104K 
                Comprehensive Loss                                               
18: R6          Consolidated Statements of Convertible Preferred    HTML    117K 
                Stock, Redeemable Common Stock and Stockholders'                 
                Equity (Deficit)                                                 
19: R7          Consolidated Statements of Cash Flows               HTML    120K 
20: R8          Nature of the Business and Basis of Presentation    HTML     37K 
21: R9          Summary of Significant Accounting Policies          HTML     88K 
22: R10         License, Collaboration, and Funding Agreements      HTML     47K 
23: R11         Fair Value of Financial Assets and Liabilities      HTML    129K 
24: R12         Property and Equipment, Net                         HTML     40K 
25: R13         Accrued Expenses                                    HTML     37K 
26: R14         Long-Term Debt                                      HTML     57K 
27: R15         Leases                                              HTML     56K 
28: R16         Commitment and Contingencies                        HTML     33K 
29: R17         Preferred and Common Stock Warrants                 HTML     81K 
30: R18         Common Stock, Redeemable Common Stock and           HTML     48K 
                Convertible Preferred Stock (converted to Common                 
                Stock)                                                           
31: R19         Stock-Based Compensation                            HTML     87K 
32: R20         Income Taxes                                        HTML     89K 
33: R21         Net Loss per Share                                  HTML     52K 
34: R22         Loss on Transfer of Nonfinancial Assets             HTML     31K 
35: R23         Summary of Significant Accounting Policies          HTML    117K 
                (Policies)                                                       
36: R24         Summary of Significant Accounting Policies          HTML     55K 
                (Tables)                                                         
37: R25         Fair Value of Financial Assets and Liabilities      HTML    137K 
                (Tables)                                                         
38: R26         Property and Equipment, Net (Tables)                HTML     39K 
39: R27         Accrued Expenses (Tables)                           HTML     37K 
40: R28         Long-Term Debt (Tables)                             HTML     52K 
41: R29         Leases (Tables)                                     HTML     55K 
42: R30         Preferred and Common Stock Warrants (Tables)        HTML     78K 
43: R31         Stock-Based Compensation (Tables)                   HTML     75K 
44: R32         Income Taxes (Tables)                               HTML     88K 
45: R33         Net Loss per Share (Tables)                         HTML     52K 
46: R34         Nature of the Business and Basis of Presentation    HTML     56K 
                (Details)                                                        
47: R35         Summary of Significant Accounting Policies -        HTML     46K 
                Schedule of Restricted Cash (Details)                            
48: R36         Summary of Significant Accounting Policies -        HTML     39K 
                Schedule of Cash, Cash Equivalents and Restricted                
                Cash (Details)                                                   
49: R37         Summary of Significant Accounting Policies -        HTML     40K 
                Schedule of Property, Plant and Equipment                        
                (Details)                                                        
50: R38         Summary of Significant Policies - Additional        HTML     38K 
                Information (Details)                                            
51: R39         License, Collaboration, and Funding Agreements -    HTML     54K 
                Genzyme Agreement (Details)                                      
52: R40         License, Collaboration, and Funding Agreements -    HTML     39K 
                Georgetown Agreement (Details)                                   
53: R41         License, Collaboration, and Funding Agreements -    HTML     47K 
                Beth Israel Deaconess Medical Center Agreements                  
                (Details)                                                        
54: R42         License, Collaboration, and Funding Agreements -    HTML     41K 
                Research and Development Incentive Program                       
                (Details)                                                        
55: R43         License, Collaboration, and Funding Agreements      HTML     30K 
                (Details)                                                        
56: R44         Fair Value of Financial Assets and Liabilities -    HTML     74K 
                Measured on a Recurring Basis (Details)                          
57: R45         Fair Value of Financial Assets and Liabilities -    HTML     45K 
                Debt Securities Available-for-Sale (Details)                     
58: R46         Fair Value of Financial Assets and Liabilities -    HTML     53K 
                Narrative (Details)                                              
59: R47         Fair Value of Financial Assets and Liabilities      HTML     55K 
                -Aggregate Fair Value of Warrant and Derivative                  
                Liabilities (Details)                                            
60: R48         Fair Value of Financial Assets and Liabilities -    HTML     50K 
                Assumptions (Details)                                            
61: R49         Fair Value of Financial Assets and Liabilities -    HTML     42K 
                Goodwill Rollforward (Details)                                   
62: R50         Property and Equipment, Net (Details)               HTML     49K 
63: R51         Accrued Expenses (Details)                          HTML     39K 
64: R52         Long-Term Debt - Schedule of Long-Term Debt         HTML     41K 
                (Details)                                                        
65: R53         Long-Term Debt - Narrative (Details)                HTML     63K 
66: R54         Long-Term Debt - Hercules Loan Agreements           HTML     35K 
                (Details)                                                        
67: R55         Long-Term Debt - Future Principal Payments          HTML     37K 
                (Details)                                                        
68: R56         Leases (Details)                                    HTML     79K 
69: R57         Leases - Schedule of Components of Lease Expense    HTML     47K 
                (Details)                                                        
70: R58         Leases - Schedule of Maturities of Lease            HTML     44K 
                Liabilities (Detail)                                             
71: R59         Preferred and Common Stock Warrants - Additional    HTML     84K 
                Information (Details)                                            
72: R60         Preferred and Common Stock Warrants - Schedule of   HTML     50K 
                Outstanding Warrants (Detail)                                    
73: R61         Preferred and Common Stock Warrants - Summary of    HTML    103K 
                Outstanding Warrants to Purchase Shares of Common                
                Stock (Details)                                                  
74: R62         Common Stock, Redeemable Common Stock and           HTML    192K 
                Convertible Preferred Stock (converted to Common                 
                Stock) - Additional Information (Details)                        
75: R63         Stock-Based Compensation - Additional Information   HTML     94K 
                (Details)                                                        
76: R64         Stock-Based Compensation - Summary of Stock Option  HTML     79K 
                Activity (Detail)                                                
77: R65         Stock-Based Compensation - Restricted Stock Units   HTML     38K 
                (Details)                                                        
78: R66         Stock-Based Compensation - Summary of Stock-Based   HTML     42K 
                Compensation Expense Classification (Details)                    
79: R67         Stock-Based Compensation - Stock Option Valuation   HTML     52K 
                (Details)                                                        
80: R68         Income Taxes - Schedule of Income Loss Before       HTML     37K 
                Income Taxes (Details)                                           
81: R69         Income Taxes - Reconciliation of Effective Income   HTML     44K 
                Tax Rate (Details)                                               
82: R70         Income Taxes - Deferred Income Tax Asset (Details)  HTML     50K 
83: R71         Income Taxes - Narrative (Details)                  HTML     48K 
84: R72         Income Taxes - Deferred Tax Valuation Allowance     HTML     33K 
                (Details)                                                        
85: R73         Income Taxes (Details)                              HTML     31K 
86: R74         Net Loss per Share - Summary of Basic and Diluted   HTML     65K 
                Net loss per Share Attributable to Common                        
                Stockholders (Details)                                           
87: R75         Net Loss per Share - Additional Information         HTML     39K 
                (Details)                                                        
88: R76         Net Loss per Share - Schedule of Anti-dilutive      HTML     38K 
                Securities Excluded from Computation of Diluted                  
                Net Loss per Share Attributable to Common                        
                Stockholders (Details)                                           
90: XML         IDEA XML File -- Filing Summary                      XML    170K 
93: XML         XBRL Instance -- xfor-20231231_htm                   XML   1.90M 
89: EXCEL       IDEA Workbook of Financial Report Info              XLSX    199K 
 9: EX-101.CAL  XBRL Calculations -- xfor-20231231_cal               XML    190K 
10: EX-101.DEF  XBRL Definitions -- xfor-20231231_def                XML    760K 
11: EX-101.LAB  XBRL Labels -- xfor-20231231_lab                     XML   1.70M 
12: EX-101.PRE  XBRL Presentations -- xfor-20231231_pre              XML   1.22M 
 8: EX-101.SCH  XBRL Schema -- xfor-20231231                         XSD    212K 
91: JSON        XBRL Instance as JSON Data -- MetaLinks              523±   804K 
92: ZIP         XBRL Zipped Folder -- 0001628280-24-012578-xbrl      Zip    586K

‘XML’   —   IDEA XML File — Filing Summary

This Document is an IDEA XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<FilingSummary>
<Version> 3.24.1 </Version>
<ProcessingTime/>
<ReportFormat> html </ReportFormat>
<ContextCount> 296 </ContextCount>
<ElementCount> 388 </ElementCount>
<EntityCount> 1 </EntityCount>
<FootnotesReported> false </FootnotesReported>
<SegmentCount> 100 </SegmentCount>
<ScenarioCount> 0 </ScenarioCount>
<TuplesReported> false </TuplesReported>
<UnitCount> 6 </UnitCount>
<MyReports>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R1.htm </HtmlFileName>
<LongName> 0000001 - Document - Cover </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/Cover </Role>
<ShortName> Cover </ShortName>
<MenuCategory> Cover </MenuCategory>
<Position> 1 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R2.htm </HtmlFileName>
<LongName> 0000002 - Document - Audit Information </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/AuditInformation </Role>
<ShortName> Audit Information </ShortName>
<MenuCategory> Cover </MenuCategory>
<Position> 2 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R3.htm </HtmlFileName>
<LongName> 0000003 - Statement - Consolidated Balance Sheets </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/ConsolidatedBalanceSheets </Role>
<ShortName> Consolidated Balance Sheets </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 3 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R4.htm </HtmlFileName>
<LongName> 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/ConsolidatedBalanceSheetsParenthetical </Role>
<ShortName> Consolidated Balance Sheets (Parenthetical) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 4 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R5.htm </HtmlFileName>
<LongName> 0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss </Role>
<ShortName> Consolidated Statements of Operations and Comprehensive Loss </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 5 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R6.htm </HtmlFileName>
<LongName> 0000006 - Statement - Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/ConsolidatedStatementsofConvertiblePreferredStockRedeemableCommonStockandStockholdersEquityDeficit </Role>
<ShortName> Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 6 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R7.htm </HtmlFileName>
<LongName> 0000007 - Statement - Consolidated Statements of Cash Flows </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/ConsolidatedStatementsofCashFlows </Role>
<ShortName> Consolidated Statements of Cash Flows </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 7 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R8.htm </HtmlFileName>
<LongName> 0000008 - Disclosure - Nature of the Business and Basis of Presentation </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation </Role>
<ShortName> Nature of the Business and Basis of Presentation </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 8 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R9.htm </HtmlFileName>
<LongName> 0000009 - Disclosure - Summary of Significant Accounting Policies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies </Role>
<ShortName> Summary of Significant Accounting Policies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 9 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R10.htm </HtmlFileName>
<LongName> 0000010 - Disclosure - License, Collaboration, and Funding Agreements </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements </Role>
<ShortName> License, Collaboration, and Funding Agreements </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 10 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R11.htm </HtmlFileName>
<LongName> 0000011 - Disclosure - Fair Value of Financial Assets and Liabilities </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities </Role>
<ShortName> Fair Value of Financial Assets and Liabilities </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 11 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R12.htm </HtmlFileName>
<LongName> 0000012 - Disclosure - Property and Equipment, Net </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/PropertyandEquipmentNet </Role>
<ShortName> Property and Equipment, Net </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 12 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R13.htm </HtmlFileName>
<LongName> 0000013 - Disclosure - Accrued Expenses </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/AccruedExpenses </Role>
<ShortName> Accrued Expenses </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 13 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R14.htm </HtmlFileName>
<LongName> 0000014 - Disclosure - Long-Term Debt </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LongTermDebt </Role>
<ShortName> Long-Term Debt </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 14 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R15.htm </HtmlFileName>
<LongName> 0000015 - Disclosure - Leases </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/Leases </Role>
<ShortName> Leases </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 15 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R16.htm </HtmlFileName>
<LongName> 0000016 - Disclosure - Commitment and Contingencies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/CommitmentandContingencies </Role>
<ShortName> Commitment and Contingencies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 16 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R17.htm </HtmlFileName>
<LongName> 0000017 - Disclosure - Preferred and Common Stock Warrants </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/PreferredandCommonStockWarrants </Role>
<ShortName> Preferred and Common Stock Warrants </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 17 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R18.htm </HtmlFileName>
<LongName> 0000018 - Disclosure - Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock </Role>
<ShortName> Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock) </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 18 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R19.htm </HtmlFileName>
<LongName> 0000019 - Disclosure - Stock-Based Compensation </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/StockBasedCompensation </Role>
<ShortName> Stock-Based Compensation </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 19 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R20.htm </HtmlFileName>
<LongName> 0000020 - Disclosure - Income Taxes </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/IncomeTaxes </Role>
<ShortName> Income Taxes </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 20 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R21.htm </HtmlFileName>
<LongName> 0000021 - Disclosure - Net Loss per Share </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/NetLossperShare </Role>
<ShortName> Net Loss per Share </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 21 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R22.htm </HtmlFileName>
<LongName> 0000022 - Disclosure - Loss on Transfer of Nonfinancial Assets </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LossonTransferofNonfinancialAssets </Role>
<ShortName> Loss on Transfer of Nonfinancial Assets </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 22 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R23.htm </HtmlFileName>
<LongName> 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesPolicies </Role>
<ShortName> Summary of Significant Accounting Policies (Policies) </ShortName>
<MenuCategory> Policies </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies </ParentRole>
<Position> 23 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R24.htm </HtmlFileName>
<LongName> 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesTables </Role>
<ShortName> Summary of Significant Accounting Policies (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/SummaryofSignificantAccountingPolicies </ParentRole>
<Position> 24 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R25.htm </HtmlFileName>
<LongName> 9954473 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables </Role>
<ShortName> Fair Value of Financial Assets and Liabilities (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilities </ParentRole>
<Position> 25 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R26.htm </HtmlFileName>
<LongName> 9954474 - Disclosure - Property and Equipment, Net (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/PropertyandEquipmentNetTables </Role>
<ShortName> Property and Equipment, Net (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/PropertyandEquipmentNet </ParentRole>
<Position> 26 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R27.htm </HtmlFileName>
<LongName> 9954475 - Disclosure - Accrued Expenses (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/AccruedExpensesTables </Role>
<ShortName> Accrued Expenses (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/AccruedExpenses </ParentRole>
<Position> 27 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R28.htm </HtmlFileName>
<LongName> 9954476 - Disclosure - Long-Term Debt (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LongTermDebtTables </Role>
<ShortName> Long-Term Debt (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/LongTermDebt </ParentRole>
<Position> 28 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R29.htm </HtmlFileName>
<LongName> 9954477 - Disclosure - Leases (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LeasesTables </Role>
<ShortName> Leases (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/Leases </ParentRole>
<Position> 29 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R30.htm </HtmlFileName>
<LongName> 9954478 - Disclosure - Preferred and Common Stock Warrants (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/PreferredandCommonStockWarrantsTables </Role>
<ShortName> Preferred and Common Stock Warrants (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/PreferredandCommonStockWarrants </ParentRole>
<Position> 30 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R31.htm </HtmlFileName>
<LongName> 9954479 - Disclosure - Stock-Based Compensation (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/StockBasedCompensationTables </Role>
<ShortName> Stock-Based Compensation (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/StockBasedCompensation </ParentRole>
<Position> 31 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R32.htm </HtmlFileName>
<LongName> 9954480 - Disclosure - Income Taxes (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/IncomeTaxesTables </Role>
<ShortName> Income Taxes (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/IncomeTaxes </ParentRole>
<Position> 32 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R33.htm </HtmlFileName>
<LongName> 9954481 - Disclosure - Net Loss per Share (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/NetLossperShareTables </Role>
<ShortName> Net Loss per Share (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/NetLossperShare </ParentRole>
<Position> 33 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R34.htm </HtmlFileName>
<LongName> 9954482 - Disclosure - Nature of the Business and Basis of Presentation (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentationDetails </Role>
<ShortName> Nature of the Business and Basis of Presentation (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/NatureoftheBusinessandBasisofPresentation </ParentRole>
<Position> 34 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R35.htm </HtmlFileName>
<LongName> 9954483 - Disclosure - Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashDetails </Role>
<ShortName> Summary of Significant Accounting Policies - Schedule of Restricted Cash (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 35 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R36.htm </HtmlFileName>
<LongName> 9954484 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofCashCashEquivalentsandRestrictedCashDetails </Role>
<ShortName> Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 36 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R37.htm </HtmlFileName>
<LongName> 9954485 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/SummaryofSignificantAccountingPoliciesScheduleofPropertyPlantandEquipmentDetails </Role>
<ShortName> Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 37 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R38.htm </HtmlFileName>
<LongName> 9954486 - Disclosure - Summary of Significant Policies - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/SummaryofSignificantPoliciesAdditionalInformationDetails </Role>
<ShortName> Summary of Significant Policies - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 38 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R39.htm </HtmlFileName>
<LongName> 9954487 - Disclosure - License, Collaboration, and Funding Agreements - Genzyme Agreement (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGenzymeAgreementDetails </Role>
<ShortName> License, Collaboration, and Funding Agreements - Genzyme Agreement (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 39 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R40.htm </HtmlFileName>
<LongName> 9954488 - Disclosure - License, Collaboration, and Funding Agreements - Georgetown Agreement (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsGeorgetownAgreementDetails </Role>
<ShortName> License, Collaboration, and Funding Agreements - Georgetown Agreement (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 40 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R41.htm </HtmlFileName>
<LongName> 9954489 - Disclosure - License, Collaboration, and Funding Agreements - Beth Israel Deaconess Medical Center Agreements (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsBethIsraelDeaconessMedicalCenterAgreementsDetails </Role>
<ShortName> License, Collaboration, and Funding Agreements - Beth Israel Deaconess Medical Center Agreements (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 41 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R42.htm </HtmlFileName>
<LongName> 9954490 - Disclosure - License, Collaboration, and Funding Agreements - Research and Development Incentive Program (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsResearchandDevelopmentIncentiveProgramDetails </Role>
<ShortName> License, Collaboration, and Funding Agreements - Research and Development Incentive Program (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 42 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R43.htm </HtmlFileName>
<LongName> 9954491 - Disclosure - License, Collaboration, and Funding Agreements (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreementsDetails </Role>
<ShortName> License, Collaboration, and Funding Agreements (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/LicenseCollaborationandFundingAgreements </ParentRole>
<Position> 43 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R44.htm </HtmlFileName>
<LongName> 9954492 - Disclosure - Fair Value of Financial Assets and Liabilities - Measured on a Recurring Basis (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails </Role>
<ShortName> Fair Value of Financial Assets and Liabilities - Measured on a Recurring Basis (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 44 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R45.htm </HtmlFileName>
<LongName> 9954493 - Disclosure - Fair Value of Financial Assets and Liabilities - Debt Securities Available-for-Sale (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesDebtSecuritiesAvailableforSaleDetails </Role>
<ShortName> Fair Value of Financial Assets and Liabilities - Debt Securities Available-for-Sale (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 45 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R46.htm </HtmlFileName>
<LongName> 9954494 - Disclosure - Fair Value of Financial Assets and Liabilities - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesNarrativeDetails </Role>
<ShortName> Fair Value of Financial Assets and Liabilities - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 46 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R47.htm </HtmlFileName>
<LongName> 9954495 - Disclosure - Fair Value of Financial Assets and Liabilities -Aggregate Fair Value of Warrant and Derivative Liabilities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAggregateFairValueofWarrantandDerivativeLiabilitiesDetails </Role>
<ShortName> Fair Value of Financial Assets and Liabilities -Aggregate Fair Value of Warrant and Derivative Liabilities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 47 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R48.htm </HtmlFileName>
<LongName> 9954496 - Disclosure - Fair Value of Financial Assets and Liabilities - Assumptions (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesAssumptionsDetails </Role>
<ShortName> Fair Value of Financial Assets and Liabilities - Assumptions (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 48 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R49.htm </HtmlFileName>
<LongName> 9954497 - Disclosure - Fair Value of Financial Assets and Liabilities - Goodwill Rollforward (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/FairValueofFinancialAssetsandLiabilitiesGoodwillRollforwardDetails </Role>
<ShortName> Fair Value of Financial Assets and Liabilities - Goodwill Rollforward (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 49 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R50.htm </HtmlFileName>
<LongName> 9954498 - Disclosure - Property and Equipment, Net (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/PropertyandEquipmentNetDetails </Role>
<ShortName> Property and Equipment, Net (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/PropertyandEquipmentNetTables </ParentRole>
<Position> 50 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R51.htm </HtmlFileName>
<LongName> 9954499 - Disclosure - Accrued Expenses (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/AccruedExpensesDetails </Role>
<ShortName> Accrued Expenses (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/AccruedExpensesTables </ParentRole>
<Position> 51 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R52.htm </HtmlFileName>
<LongName> 9954500 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LongTermDebtScheduleofLongTermDebtDetails </Role>
<ShortName> Long-Term Debt - Schedule of Long-Term Debt (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 52 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R53.htm </HtmlFileName>
<LongName> 9954501 - Disclosure - Long-Term Debt - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LongTermDebtNarrativeDetails </Role>
<ShortName> Long-Term Debt - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 53 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R54.htm </HtmlFileName>
<LongName> 9954502 - Disclosure - Long-Term Debt - Hercules Loan Agreements (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LongTermDebtHerculesLoanAgreementsDetails </Role>
<ShortName> Long-Term Debt - Hercules Loan Agreements (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 54 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R55.htm </HtmlFileName>
<LongName> 9954503 - Disclosure - Long-Term Debt - Future Principal Payments (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LongTermDebtFuturePrincipalPaymentsDetails </Role>
<ShortName> Long-Term Debt - Future Principal Payments (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 55 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R56.htm </HtmlFileName>
<LongName> 9954504 - Disclosure - Leases (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LeasesDetails </Role>
<ShortName> Leases (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/LeasesTables </ParentRole>
<Position> 56 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R57.htm </HtmlFileName>
<LongName> 9954505 - Disclosure - Leases - Schedule of Components of Lease Expense (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails </Role>
<ShortName> Leases - Schedule of Components of Lease Expense (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 57 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R58.htm </HtmlFileName>
<LongName> 9954506 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetail </Role>
<ShortName> Leases - Schedule of Maturities of Lease Liabilities (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 58 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R59.htm </HtmlFileName>
<LongName> 9954507 - Disclosure - Preferred and Common Stock Warrants - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/PreferredandCommonStockWarrantsAdditionalInformationDetails </Role>
<ShortName> Preferred and Common Stock Warrants - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 59 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R60.htm </HtmlFileName>
<LongName> 9954508 - Disclosure - Preferred and Common Stock Warrants - Schedule of Outstanding Warrants (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/PreferredandCommonStockWarrantsScheduleofOutstandingWarrantsDetail </Role>
<ShortName> Preferred and Common Stock Warrants - Schedule of Outstanding Warrants (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 60 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R61.htm </HtmlFileName>
<LongName> 9954509 - Disclosure - Preferred and Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/PreferredandCommonStockWarrantsSummaryofOutstandingWarrantstoPurchaseSharesofCommonStockDetails </Role>
<ShortName> Preferred and Common Stock Warrants - Summary of Outstanding Warrants to Purchase Shares of Common Stock (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 61 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R62.htm </HtmlFileName>
<LongName> 9954510 - Disclosure - Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock) - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStockAdditionalInformationDetails </Role>
<ShortName> Common Stock, Redeemable Common Stock and Convertible Preferred Stock (converted to Common Stock) - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/CommonStockRedeemableCommonStockandConvertiblePreferredStockconvertedtoCommonStock </ParentRole>
<Position> 62 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R63.htm </HtmlFileName>
<LongName> 9954511 - Disclosure - Stock-Based Compensation - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/StockBasedCompensationAdditionalInformationDetails </Role>
<ShortName> Stock-Based Compensation - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 63 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R64.htm </HtmlFileName>
<LongName> 9954512 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockOptionActivityDetail </Role>
<ShortName> Stock-Based Compensation - Summary of Stock Option Activity (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 64 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R65.htm </HtmlFileName>
<LongName> 9954513 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/StockBasedCompensationRestrictedStockUnitsDetails </Role>
<ShortName> Stock-Based Compensation - Restricted Stock Units (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 65 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R66.htm </HtmlFileName>
<LongName> 9954514 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseClassificationDetails </Role>
<ShortName> Stock-Based Compensation - Summary of Stock-Based Compensation Expense Classification (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 66 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R67.htm </HtmlFileName>
<LongName> 9954515 - Disclosure - Stock-Based Compensation - Stock Option Valuation (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/StockBasedCompensationStockOptionValuationDetails </Role>
<ShortName> Stock-Based Compensation - Stock Option Valuation (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 67 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R68.htm </HtmlFileName>
<LongName> 9954516 - Disclosure - Income Taxes - Schedule of Income Loss Before Income Taxes (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails </Role>
<ShortName> Income Taxes - Schedule of Income Loss Before Income Taxes (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 68 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R69.htm </HtmlFileName>
<LongName> 9954517 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails </Role>
<ShortName> Income Taxes - Reconciliation of Effective Income Tax Rate (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 69 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R70.htm </HtmlFileName>
<LongName> 9954518 - Disclosure - Income Taxes - Deferred Income Tax Asset (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/IncomeTaxesDeferredIncomeTaxAssetDetails </Role>
<ShortName> Income Taxes - Deferred Income Tax Asset (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 70 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R71.htm </HtmlFileName>
<LongName> 9954519 - Disclosure - Income Taxes - Narrative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/IncomeTaxesNarrativeDetails </Role>
<ShortName> Income Taxes - Narrative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 71 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R72.htm </HtmlFileName>
<LongName> 9954520 - Disclosure - Income Taxes - Deferred Tax Valuation Allowance (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/IncomeTaxesDeferredTaxValuationAllowanceDetails </Role>
<ShortName> Income Taxes - Deferred Tax Valuation Allowance (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 72 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R73.htm </HtmlFileName>
<LongName> 9954521 - Disclosure - Income Taxes (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/IncomeTaxesDetails </Role>
<ShortName> Income Taxes (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.x4pharma.com/role/IncomeTaxesTables </ParentRole>
<Position> 73 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R74.htm </HtmlFileName>
<LongName> 9954522 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/NetLossperShareSummaryofBasicandDilutedNetlossperShareAttributabletoCommonStockholdersDetails </Role>
<ShortName> Net Loss per Share - Summary of Basic and Diluted Net loss per Share Attributable to Common Stockholders (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 74 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R75.htm </HtmlFileName>
<LongName> 9954523 - Disclosure - Net Loss per Share - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/NetLossperShareAdditionalInformationDetails </Role>
<ShortName> Net Loss per Share - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 75 </Position>
</Report>
<Report instance="xfor-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R76.htm </HtmlFileName>
<LongName> 9954524 - Disclosure - Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.x4pharma.com/role/NetLossperShareScheduleofAntidilutiveSecuritiesExcludedfromComputationofDilutedNetLossperShareAttributabletoCommonStockholdersDetails </Role>
<ShortName> Net Loss per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 76 </Position>
</Report>
<Report>
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<LongName> All Reports </LongName>
<ReportType> Book </ReportType>
<ShortName> All Reports </ShortName>
</Report>
</MyReports>
<Logs>
<Log type="Warning"> [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 12 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentType, dei:EntityAddressAddressLine1, dei:EntityAddressAddressLine2, dei:EntityAddressCityOrTown, dei:EntityAddressPostalZipCode, dei:EntityAddressStateOrProvince, dei:EntityIncorporationStateCountryCode, us-gaap:IntangibleAssetsDisclosureTextBlock, us-gaap:NumberOfReportingUnits, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, xfor:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag, xfor:OperatingLeaseRightOfUseAssetAmortizationTerm - xfor-20231231.htm 4 </Log>
</Logs>
<InputFiles>
<File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="xfor-20231231.htm"> xfor-20231231.htm </File>
<File> xfor-20231231.xsd </File>
<File> xfor-20231231_cal.xml </File>
<File> xfor-20231231_def.xml </File>
<File> xfor-20231231_lab.xml </File>
<File> xfor-20231231_pre.xml </File>
</InputFiles>
<SupplementalFiles>
<File> xfor-20231231_g1.jpg </File>
</SupplementalFiles>
<BaseTaxonomies>
<BaseTaxonomy items="860"> http://fasb.org/us-gaap/2023 </BaseTaxonomy>
<BaseTaxonomy items="46"> http://xbrl.sec.gov/dei/2023 </BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase> true </HasPresentationLinkbase>
<HasCalculationLinkbase> true </HasCalculationLinkbase>
</FilingSummary>

28 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/09/23  X4 Pharmaceuticals, Inc.          10-Q        9/30/23   75:6.9M                                   Workiva Inc Wde… FA01/FA
 8/10/23  X4 Pharmaceuticals, Inc.          10-Q        6/30/23   76:7.4M                                   Workiva Inc Wde… FA01/FA
 5/16/23  X4 Pharmaceuticals, Inc.          8-K:1,3,7,8 5/15/23   16:4.6M                                   Workiva Inc Wde… FA01/FA
 3/21/23  X4 Pharmaceuticals, Inc.          10-K       12/31/22   96:34M                                    Workiva Inc Wde… FA01/FA
12/09/22  X4 Pharmaceuticals, Inc.          8-K:1,8    12/06/22   16:953K                                   Workiva Inc Wde… FA01/FA
11/09/22  X4 Pharmaceuticals, Inc.          8-K:5      11/07/22   11:265K                                   Workiva Inc Wde… FA01/FA
 9/01/22  X4 Pharmaceuticals, Inc.          8-K:3,5     9/01/22   11:2.9M                                   Workiva Inc Wde… FA01/FA
 7/01/22  X4 Pharmaceuticals, Inc.          8-K:1,2,3,8 6/30/22   16:1M                                     Workiva Inc Wde… FA01/FA
 3/17/22  X4 Pharmaceuticals, Inc.          10-K       12/31/21  100:10M                                    Workiva Inc Wde… FA01/FA
 3/03/22  X4 Pharmaceuticals, Inc.          8-K:1,3,8   3/03/22   13:744K                                   Workiva Inc Wde… FA01/FA
 1/14/22  X4 Pharmaceuticals, Inc.          8-K:1,9     1/14/22   13:727K                                   Workiva Inc Wde… FA01/FA
11/05/21  X4 Pharmaceuticals, Inc.          8-K:1,3    11/05/21   13:735K                                   Workiva Inc Wde… FA01/FA
 3/19/21  X4 Pharmaceuticals, Inc.          10-K       12/31/20  100:12M                                    Workiva Inc Wde… FA01/FA
 3/19/21  X4 Pharmaceuticals, Inc.          8-K:1,2,3,8 3/18/21   17:1M                                     Workiva Inc Wde… FA01/FA
 8/07/20  X4 Pharmaceuticals, Inc.          S-3                    8:1.3M                                   Donnelley … Solutions/FA
 6/10/20  X4 Pharmaceuticals, Inc.          S-8         6/10/20    5:331K                                   Workiva Inc Wde… FA01/FA
 5/07/20  X4 Pharmaceuticals, Inc.          10-Q        3/31/20   73:7.2M                                   Workiva Inc Wde… FA01/FA
 3/12/20  X4 Pharmaceuticals, Inc.          10-K       12/31/19  115:15M                                    Workiva Inc Wde… FA01/FA
11/27/19  X4 Pharmaceuticals, Inc.          8-K:1,8,9  11/25/19    7:474K                                   Donnelley … Solutions/FA
 6/19/19  X4 Pharmaceuticals, Inc.          8-K:5,9     6/17/19    7:265K                                   Donnelley … Solutions/FA
 5/13/19  X4 Pharmaceuticals, Inc.          8-K/A:9     3/11/19    5:543K                                   Donnelley … Solutions/FA
 4/15/19  X4 Pharmaceuticals, Inc.          8-K:1,8,9   4/12/19    6:455K                                   Donnelley … Solutions/FA
 4/03/19  X4 Pharmaceuticals, Inc.          8-K/A:9     3/11/19    5:912K                                   Donnelley … Solutions/FA
 3/13/19  X4 Pharmaceuticals, Inc.          8-K:2,3,5,8 3/11/19   22:2.6M                                   Donnelley … Solutions/FA
11/27/18  X4 Pharmaceuticals, Inc.          8-K:1,5,7,811/26/18   10:8.9M                                   Donnelley … Solutions/FA
11/20/17  X4 Pharmaceuticals, Inc.          8-K:5,9    11/20/17    3:176K                                   Donnelley … Solutions/FA
11/06/17  X4 Pharmaceuticals, Inc.          S-1/A                  8:4.3M                                   Donnelley … Solutions/FA
10/20/17  X4 Pharmaceuticals, Inc.          S-1                   49:9.2M                                   Donnelley … Solutions/FA
↑Top
Filing Submission 0001628280-24-012578   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 15, 8:39:36.3pm ET